| Year |
Citation |
Score |
| 2021 |
Fitzgerald AA, Wang S, Agarwal V, Marcisak EF, Zuo A, Jablonski SA, Loth M, Fertig EJ, MacDougall J, Zhukovsky E, Trivedi S, Bhatia D, O'Neill V, Weiner LM. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Journal For Immunotherapy of Cancer. 9. PMID 34737215 DOI: 10.1136/jitc-2021-002837 |
0.326 |
|
| 2021 |
Davis-Marcisak EF, Fitzgerald AA, Kessler MD, Danilova L, Jaffee EM, Zaidi N, Weiner LM, Fertig EJ. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. Genome Medicine. 13: 129. PMID 34376232 DOI: 10.1186/s13073-021-00944-5 |
0.34 |
|
| 2021 |
Ajina R, Malchiodi ZX, Fitzgerald AA, Zuo A, Wang S, Moussa M, Cooper CJ, Shen Y, Johnson QR, Parks JM, Smith JC, Catalfamo M, Fertig EJ, Jablonski SA, Weiner LM. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Cancer Immunology Research. PMID 33509790 DOI: 10.1158/2326-6066.CIR-20-0272 |
0.331 |
|
| 2021 |
Malchiodi ZX, Weiner LM. Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma. Cancers. 13. PMID 33499238 DOI: 10.3390/cancers13030405 |
0.351 |
|
| 2020 |
Ajina R, Weiner LM. T-Cell Immunity in Pancreatic Cancer. Pancreas. 49: 1014-1023. PMID 32833941 DOI: 10.1097/Mpa.0000000000001621 |
0.42 |
|
| 2020 |
Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel, Switzerland). 9. PMID 32698317 DOI: 10.3390/Antib9030034 |
0.516 |
|
| 2020 |
Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32669374 DOI: 10.1158/1078-0432.Ccr-20-1301 |
0.321 |
|
| 2020 |
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Reviews. PMID 32601975 DOI: 10.1007/S10555-020-09909-3 |
0.306 |
|
| 2020 |
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack. Methods in Enzymology. 636: 299-322. PMID 32178823 DOI: 10.1016/Bs.Mie.2019.06.002 |
0.749 |
|
| 2020 |
Wang S, Fitzgerald A, Ajina R, Jablonsk SA, Weiner LM, MacDougall J, Agarwal V, O'Neill VJ. Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis Immunology. DOI: 10.1158/1538-7445.Am2020-6636 |
0.346 |
|
| 2019 |
Ajina R, Zahavi DJ, Zhang YW, Weiner LM. Overcoming Malignant Cell-Based Mechanisms of Resistance to Immune Checkpoint Blockade Antibodies. Seminars in Cancer Biology. PMID 31866479 DOI: 10.1016/J.Semcancer.2019.12.005 |
0.48 |
|
| 2019 |
Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, ... ... Weiner LM, et al. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. Journal of Cancer Survivorship : Research and Practice. PMID 31686365 DOI: 10.1007/S11764-019-00826-1 |
0.302 |
|
| 2019 |
Zahavi DJ, Weiner LM. Tumor mechanisms of resistance to immune attack. Progress in Molecular Biology and Translational Science. 164: 61-100. PMID 31383409 DOI: 10.1016/Bs.Pmbts.2019.03.009 |
0.407 |
|
| 2019 |
Ajina R, Zamalin D, Zuo A, Moussa M, Catalfamo M, Jablonski SA, Weiner LM. SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice. Oncoimmunology. 8: e1577127. PMID 31069138 DOI: 10.1080/2162402X.2019.1577127 |
0.405 |
|
| 2019 |
Zahavi DJ, Weiner LM. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. International Journal of Molecular Sciences. 20. PMID 30621125 DOI: 10.3390/Ijms20010158 |
0.421 |
|
| 2019 |
O'Connell A, Wang S, Weiner LM. Abstract A096: The potential role of fibroblast activation protein as a natural killer cell immune checkpoint Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A096 |
0.406 |
|
| 2019 |
Ajina R, Zuo A, Moussa M, Cooper SJ, Shen Y, Johnson QR, Parks JM, Smith JC, Fertig E, Catalfamo M, Jablonski SA, Weiner LM. Abstract 4584: Malignant pancreatic cancer cells respond to immune selection pressure to foster immunosuppression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4584 |
0.369 |
|
| 2018 |
Zahavi D, AlDeghaither D, O'Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antibody Therapeutics. 1: 7-12. PMID 33928217 DOI: 10.1093/abt/tby002 |
0.372 |
|
| 2018 |
Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang Y, O'Connell A, Ma J, Jablonski SA, Weiner LM. A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunology Research. PMID 30563830 DOI: 10.1158/2326-6066.Cir-18-0266 |
0.433 |
|
| 2018 |
Ajina R, Zamalin D, Weiner LM. Functional genomics: paving the way for more successful cancer immunotherapy. Briefings in Functional Genomics. PMID 29762641 DOI: 10.1093/Bfgp/Ely017 |
0.411 |
|
| 2018 |
Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Letters. PMID 29746929 DOI: 10.1016/J.Canlet.2018.05.009 |
0.339 |
|
| 2018 |
Yuan H, Wang X, Shi C, Jin L, Hu J, Zhang A, Li J, Vijayendra N, Doodala V, Weiss S, Tang Y, Weiner LM, Glazer RI. Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis. Scientific Reports. 8: 5717. PMID 29632317 DOI: 10.1038/S41598-018-24022-W |
0.414 |
|
| 2018 |
Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. PMID 29579325 DOI: 10.1002/Cncr.31309 |
0.304 |
|
| 2018 |
Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. PMID 29392450 DOI: 10.1007/S00280-018-3533-8 |
0.401 |
|
| 2017 |
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio-Protocol. 7. PMID 29250574 DOI: 10.21769/BioProtoc.2435 |
0.726 |
|
| 2017 |
Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunology, Immunotherapy : Cii. PMID 29043413 DOI: 10.1007/S00262-017-2077-9 |
0.481 |
|
| 2017 |
Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Kim Lyerly H, Hartman ZC, Weiner LM. An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer Immunology, Immunotherapy : Cii. PMID 28770278 DOI: 10.1007/S00262-017-2047-2 |
0.426 |
|
| 2017 |
Aldeghaither DS, Murray JC, Roth SM, Fertig EJ, Tang S, Jablonski SA, Weiner LM. Induction of tumor cell-based ADCC resistance to create new tumor cell survival and therapy resistance mechanisms. Journal of Clinical Oncology. 35: 130-130. DOI: 10.1200/Jco.2017.35.7_Suppl.130 |
0.41 |
|
| 2017 |
Salem ME, Xiu J, Weinberg BA, El-Deiry WS, Weiner LM, Gatalica Z, Liu Z, El Ghazaly H, Xiao N, Hwang JJ, Philip PA, Shields AF, Lenz H, Marshall J. Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. Journal of Clinical Oncology. 35: 530-530. DOI: 10.1200/Jco.2017.35.4_Suppl.530 |
0.386 |
|
| 2017 |
Wood LV, Roberson BD, Agarwal PK, Apolo AB, Stroncek D, Weiner LM, Morris JC, Terabe M, Lee M, Trepel JB, Berzofsky JA. Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells. Journal of Clinical Oncology. 35: 3089-3089. DOI: 10.1200/Jco.2017.35.15_Suppl.3089 |
0.402 |
|
| 2017 |
Smith JP, Wang S, Weiner L, Nadella S. Abstract LB-133: De novo expression of gastrin and CCK-B receptors in cell lines derived from KPC mice Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-133 |
0.388 |
|
| 2017 |
Aldeghaither DS, Murray JC, Roth SM, Fertig EJ, Tang S, Jablonski SA, Weiner LM. Abstract 633: Induction of ADCC resistance profoundly alters tumor cell phenotype and stress response Cancer Research. 77: 633-633. DOI: 10.1158/1538-7445.Am2017-633 |
0.424 |
|
| 2017 |
Bhuvaneshwar K, Belouali A, Rao S, Alaoui A, Gusev Y, Clarke R, Weiner LM, Madhavan S. Abstract 2604: The Georgetown Database of Cancer (G-DOC): A web-based data sharing platform for precision medicine Cancer Research. 77: 2604-2604. DOI: 10.1158/1538-7445.Am2017-2604 |
0.327 |
|
| 2017 |
Smith J, Wang S, Nadella S, Jablonski S, Weiner L. Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival in pancreatic cancer Pancreatology. 17: S3-S4. DOI: 10.1016/J.Pan.2017.07.016 |
0.393 |
|
| 2016 |
Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. PMID 27546622 DOI: 10.1038/Onc.2016.288 |
0.743 |
|
| 2016 |
Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, ... ... Weiner LM, et al. Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27384421 DOI: 10.1158/1078-0432.Ccr-16-0149 |
0.408 |
|
| 2016 |
Berens EB, Sharif GM, Schmidt MO, Yan G, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A. Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene. PMID 27375028 DOI: 10.1038/Onc.2016.234 |
0.372 |
|
| 2016 |
Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters. 11: 1645-1650. PMID 26998056 DOI: 10.3892/Ol.2016.4101 |
0.304 |
|
| 2016 |
Salem ME, Wang H, Fakih M, Mikhail S, Smaglo BG, Pishvaian MJ, He AR, Weiner LM, Bekaii-Saab TS, Marshall J. An open-label, multi-center, phase 2 study of switch maintenance with TAS-102 plus bevacizumab following oxaliplatin or irinotecan-based fluoropyrimidine-containing induction chemotherapy in patients with metastatic colorectal cancer: ALEXANDRIA study. Journal of Clinical Oncology. 34: TPS3624-TPS3624. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3624 |
0.34 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Weiner LM, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.308 |
|
| 2016 |
Shuptrine CW, Fertig EJ, Salcie-Gautreaux M, Weiner LM. Abstract A142: An in vivo functional genomics screen identifies molecular determinants of adaptive immune rejection Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A142 |
0.437 |
|
| 2016 |
Khazak V, Skobeleva N, Beglyarova N, Bobrov E, Zhou Y, Jablonski SA, Weiner LM, Paz K, Astsaturov I. Abstract B07: Screening of patient-derived carcinoma cells and animal models identifies transcription as target in pancreatic cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B07 |
0.414 |
|
| 2016 |
Berens EB, Sharif GM, Schmidt MO, Shuptrine CW, Weiner LM, Glasgow E, Riegel AT, Wellstein A. Abstract B44: Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-B44 |
0.393 |
|
| 2016 |
Astsaturov I, Jablonski SA, Zhou Y, Serebriiskii I, Keren P, Weiner LM, Golemis E, Khazak V. Abstract A77: Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-A77 |
0.34 |
|
| 2016 |
Smith JP, Wang S, Reham A, Jablonski SA, Weiner LM. Abstract 4023: Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer Cancer Research. 76: 4023-4023. DOI: 10.1158/1538-7445.Am2016-4023 |
0.442 |
|
| 2015 |
Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 26507197 DOI: 10.1007/S00280-015-2855-Z |
0.4 |
|
| 2015 |
Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, ... ... Weiner LM, et al. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene. PMID 26165839 DOI: 10.1038/Onc.2015.226 |
0.753 |
|
| 2015 |
Redman JM, Hill EM, AlDeghaither D, Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology. PMID 25911943 DOI: 10.1016/J.Molimm.2015.04.002 |
0.48 |
|
| 2015 |
Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 27: 489-501. PMID 25873172 DOI: 10.1016/J.Ccell.2015.03.004 |
0.774 |
|
| 2015 |
von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 75: 1047-55. PMID 25791363 DOI: 10.1007/S00280-015-2705-Z |
0.307 |
|
| 2015 |
AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. Journal of Clinical Pharmacology. 55: S4-20. PMID 25707963 DOI: 10.1002/Jcph.407 |
0.41 |
|
| 2015 |
Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, ... ... Weiner LM, et al. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene. 34: 1083-93. PMID 24662823 DOI: 10.1038/Onc.2014.51 |
0.41 |
|
| 2015 |
Pishvaian MJ, Wang H, He AR, Ley L, Dorsch-Vogel K, Hartley ML, Carney E, Weiner LM, Smaglo BG, Brody JR, Marshall J. A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 33: 329-329. DOI: 10.1200/Jco.2015.33.3_Suppl.329 |
0.316 |
|
| 2015 |
Deeken JF, Wang H, Smaglo BG, Hwang JJ, He AR, Weiner LM, Marshall J, Giaccone G, Liu SV, Luecht J, Urso C, Spiegel JY, Cheema A, Pishvaian MJ. A phase I study of intravenous artesunate (IV AS) in patients with solid tumors. Journal of Clinical Oncology. 33: 2535-2535. DOI: 10.1200/Jco.2015.33.15_Suppl.2535 |
0.339 |
|
| 2015 |
Zhang Y, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, ... ... Weiner LM, et al. Abstract 1716: Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation Cancer Research. 75: 1716-1716. DOI: 10.1158/1538-7445.Am2015-1716 |
0.759 |
|
| 2015 |
Khazak V, Skobeleva N, Beglyarova N, Banina E, Lysenko E, Astsaturov I, Jablonski SA, Weiner LM, Serebriiskii I, Proia DA. Abstract 1465: Development of patient-derived platform to assess activity of anticancer agents in pancreatic cancer Cancer Research. 75: 1465-1465. DOI: 10.1158/1538-7445.Am2015-1465 |
0.447 |
|
| 2014 |
Larrick JW, Parren P, Huston JS, Plückthun A, Bradbury A, Tomlinson IM, Chester KA, Burton DR, Adams GP, Weiner LM, Scott JK, Alfenito MR, Veldman T, Reichert JM. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014. Mabs. 6: 1115-23. PMID 25517297 DOI: 10.4161/19420862.2014.971627 |
0.331 |
|
| 2014 |
Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunology Research. 2: 1186-98. PMID 25300860 DOI: 10.1158/2326-6066.Cir-14-0083 |
0.476 |
|
| 2014 |
Smaglo BG, Aldeghaither D, Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nature Reviews. Clinical Oncology. 11: 637-48. PMID 25265912 DOI: 10.1038/Nrclinonc.2014.159 |
0.422 |
|
| 2014 |
Surana R, Wang S, Xu W, Jablonski SA, Weiner LM. IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunology Research. 2: 1103-12. PMID 25204776 DOI: 10.1158/2326-6066.Cir-14-0103 |
0.772 |
|
| 2014 |
Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. PMID 25171298 DOI: 10.1097/Coc.0000000000000118 |
0.32 |
|
| 2014 |
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123: 3016-26. PMID 24652987 DOI: 10.1182/Blood-2013-10-533398 |
0.335 |
|
| 2014 |
Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clinical Colorectal Cancer. 13: 81-6. PMID 24512954 DOI: 10.1016/J.Clcc.2013.12.005 |
0.39 |
|
| 2014 |
Kim SS, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 278-91. PMID 24113515 DOI: 10.1038/Mt.2013.231 |
0.464 |
|
| 2014 |
Gurka MK, Kim CM, Haddad NG, Carroll J, Charabaty AC, Jackson PG, Harter KW, Hwang JJ, Weiner LM, Marshall J, Collins SP, Pishvaian MJ, Unger KR. Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma. Journal of Clinical Oncology. 32: 361-361. DOI: 10.1200/Jco.2014.32.3_Suppl.361 |
0.321 |
|
| 2014 |
He AR, Tesfaye A, Smith D, Marshall J, Pishvaian MJ, Smaglo BG, Weiner LM, Dorsch-Vogel K, Wang H. Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 32: 240-240. DOI: 10.1200/Jco.2014.32.3_Suppl.240 |
0.303 |
|
| 2014 |
Pan J, Xuan Z, Dyba M, Zhang Y, Fu Y, Roy R, Weiner LM, Chung F. Abstract 5362: Deficiencies in mismatch repair proteins induce elevated levels of acrolein-derived 1,N2-propanodeoxyguanosine and apoptosis in human colon cancer cells treated with acrolein Cancer Research. 74: 5362-5362. DOI: 10.1158/1538-7445.Am2014-5362 |
0.309 |
|
| 2013 |
Madhavan S, Gusev Y, Natarajan TG, Song L, Bhuvaneshwar K, Gauba R, Pandey A, Haddad BR, Goerlitz D, Cheema AK, Juhl H, Kallakury B, Marshall JL, Byers SW, Weiner LM. Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Frontiers in Genetics. 4: 236. PMID 24312117 DOI: 10.3389/Fgene.2013.00236 |
0.399 |
|
| 2013 |
Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biotherapy & Radiopharmaceuticals. 28: 274-82. PMID 23611188 DOI: 10.1089/Cbr.2012.1329 |
0.416 |
|
| 2013 |
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, ... ... Weiner LM, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discovery. 3: 96-111. PMID 23125191 DOI: 10.1158/2159-8290.Cd-12-0031 |
0.382 |
|
| 2013 |
Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 581-9. PMID 23104982 DOI: 10.1096/Fj.12-210377 |
0.414 |
|
| 2013 |
Pishvaian MJ, Wang H, Zhuang T, He AR, Hwang JJ, Hankin A, Ley L, White K, Littman SJ, Weiner LM, Marshall J, Brody JR. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 31: 147-147. DOI: 10.1200/Jco.2013.31.4_Suppl.147 |
0.302 |
|
| 2013 |
Smaglo BG, Wang H, Steadman K, Murray J, Pishvaian M, He AR, Hwang JJ, Subramaniam DS, Deeken JF, Weiner LM. A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab. Journal of Clinical Oncology. 31: TPS2624-TPS2624. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2624 |
0.462 |
|
| 2013 |
Deeken JF, Wang H, Marshall J, Subramaniam DS, Hwang JJ, He AR, Ramos C, Hardesty RA, Steadman K, Weiner LM, Pishvaian MJ. Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors. Journal of Clinical Oncology. 31: 2616-2616. DOI: 10.1200/Jco.2013.31.15_Suppl.2616 |
0.366 |
|
| 2013 |
Wu Z, Shivapurkar N, Marshall JL, Hwang J, Pishvaian MJ, Zhuang T, Wellstein A, Weiner LM, Ley L, He AR. Abstract 4667: Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Cancer Research. 73: 4667-4667. DOI: 10.1158/1538-7445.Am2013-4667 |
0.32 |
|
| 2013 |
Murray JC, Nasto RE, Jablonski SA, Tang Y, Weiner LM. Abstract 2847: Molecular determinants of sensitivity and resistance to tumor-directed antibody-dependent cellular cytotoxicity (ADCC). Cancer Research. 73: 2847-2847. DOI: 10.1158/1538-7445.Am2013-2847 |
0.47 |
|
| 2013 |
Sharif GM, Schmidt MO, Shuptrine C, Weiner LM, Hu Z, Riegel AT, Wellstein A. Abstract 2689: Drivers of cancer cell invasion and metastasis. Cancer Research. 73: 2689-2689. DOI: 10.1158/1538-7445.Am2013-2689 |
0.408 |
|
| 2013 |
Zhang Y, Nasto R, Clarke R, Weiner LM. Abstract 2042: TOB1 promotes cell survival in estrogen-independent estrogen receptor-positive breast cancer. Cancer Research. 73: 2042-2042. DOI: 10.1158/1538-7445.Am2013-2042 |
0.414 |
|
| 2012 |
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecular Cancer Therapeutics. 11: 2674-84. PMID 23075808 DOI: 10.1158/1535-7163.Mct-12-0692 |
0.326 |
|
| 2012 |
Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA. Mabs. 4: 648-52. PMID 23007482 DOI: 10.4161/Mabs.22221 |
0.394 |
|
| 2012 |
Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. The New England Journal of Medicine. 366: 1156-8. PMID 22435376 DOI: 10.1056/Nejmcibr1114526 |
0.356 |
|
| 2012 |
Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 148: 1081-4. PMID 22424219 DOI: 10.1016/J.Cell.2012.02.034 |
0.513 |
|
| 2012 |
Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology. 22: 3-13. PMID 22245472 DOI: 10.1016/J.Semcancer.2011.12.009 |
0.785 |
|
| 2012 |
Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology, Immunotherapy : Cii. 61: 49-61. PMID 21842208 DOI: 10.1007/S00262-011-1090-7 |
0.425 |
|
| 2012 |
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 31: 1217-27. PMID 21785464 DOI: 10.1038/Onc.2011.314 |
0.327 |
|
| 2012 |
Marshall J, Hwang JJ, Pishvaian MJ, He AR, Weiner LM, Sandene EK, Gulley JL, Heery CR, Schlom J, Speyer S, Richman J, Ferraro J, Coeshott C, Cohn A, Apelian D, et al. A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer. Journal of Clinical Oncology. 30: TPS3638-TPS3638. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps3638 |
0.425 |
|
| 2012 |
Wu Z, Marshall J, Hwang JJ, Pishvaian MJ, Wellstein A, Weiner LM, He AR. A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E14569 |
0.436 |
|
| 2012 |
Deeken JF, Wang H, Hwang JJ, Marshall J, Subramaniam DS, He AR, Weiner LM, Hardesty RA, Steadman K, Pishvaian MJ. A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors. Journal of Clinical Oncology. 30: 2590-2590. DOI: 10.1200/Jco.2012.30.15_Suppl.2590 |
0.368 |
|
| 2012 |
Murray JC, Nasto RE, Jablonski SA, Tang Y, Weiner LM. Abstract LB-128: Targeted RNAi screening of an EGFR network reveals molecular determinants of tumor cell sensitivity to antibody-dependent cellular cytotoxicity (ADCC) Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-128 |
0.492 |
|
| 2011 |
Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, Ley L, Apte SK, Littman SJ, Weiner LM, Marshall J, Brody JR. A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS170. PMID 28023043 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps170 |
0.353 |
|
| 2011 |
He AR, Hwang JJ, Marshall J, Pishvaian M, Slack R, Weiner LM, Wellstein A. A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14542. PMID 28020703 DOI: 10.1200/Jco.2011.29.15_Suppl.E14542 |
0.435 |
|
| 2011 |
Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kuda D, McAndrew T, Weiner LM, Marshall J, Brody JR. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3502. PMID 28020342 DOI: 10.1200/Jco.2011.29.15_Suppl.3502 |
0.335 |
|
| 2011 |
Liu M, Zhang J, Shaller C, Simmons H, Bingham C, Robinson MK, Adams G, Weiner LM, Borghaei H. Effective targeting of tumor vasculature with an antibody against tumor endothelial marker 7-R (TEM7R). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13040. PMID 28019850 DOI: 10.1200/Jco.2011.29.15_Suppl.E13040 |
0.43 |
|
| 2011 |
Clarke R, Shajahan AN, Wang Y, Tyson JJ, Riggins RB, Weiner LM, Bauman WT, Xuan J, Zhang B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, et al. Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical Investigation. 5: 35-44. PMID 23930139 DOI: 10.1515/Hmbci.2010.073 |
0.331 |
|
| 2011 |
Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, ... Weiner LM, et al. G-DOC: a systems medicine platform for personalized oncology. Neoplasia (New York, N.Y.). 13: 771-83. PMID 21969811 DOI: 10.1593/Neo.11806 |
0.364 |
|
| 2011 |
Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nature Reviews. Cancer. 11: 523-32. PMID 21677677 DOI: 10.1038/Nrc3081 |
0.364 |
|
| 2011 |
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Research. 71: 2250-9. PMID 21406401 DOI: 10.1158/0008-5472.Can-10-2277 |
0.434 |
|
| 2011 |
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. American Journal of Clinical Oncology. 34: 70-5. PMID 20458210 DOI: 10.1097/Coc.0B013E3181D2734A |
0.392 |
|
| 2011 |
Murray JC, Wu CS, Weiner LM. Why cetuximab is not active in the adjuvant setting Current Colorectal Cancer Reports. 7: 211-217. DOI: 10.1007/S11888-011-0103-4 |
0.453 |
|
| 2010 |
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, ... Weiner LM, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science Signaling. 3: ra67. PMID 20858866 DOI: 10.1126/Scisignal.2001083 |
0.37 |
|
| 2010 |
Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews. Immunology. 10: 317-27. PMID 20414205 DOI: 10.1038/Nri2744 |
0.768 |
|
| 2010 |
Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prevention Research (Philadelphia, Pa.). 3: 410-5. PMID 20332297 DOI: 10.1158/1940-6207.Capr-10-0040 |
0.751 |
|
| 2010 |
Wang S, Xu W, Tang Y, Surana R, Bingham C, Astsaturov IA, McCarthy K, Alpaugh RK, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Abstract LB-324: A toll-like receptor 4 agonist enhances the efficacy of trastuzumab therapy and promotes adaptive immunity and long-term protection against a human ErbB-2 (HER2)-transfected syngeneic tumor in a human HER2 transgenic mouse model Immunology. 70. DOI: 10.1158/1538-7445.Am10-Lb-324 |
0.738 |
|
| 2010 |
Sukhanova AL, Bagnyukova T, Kratz LE, Kelley RI, Serebriiskii IG, Weiner LM, Golemis EA, Astsaturov IA. Abstract 5098: Targeting the cholesterol pathway geneSC4MOLsensitizes cancer to EGFR inhibitors Cancer Research. 70: 5098-5098. DOI: 10.1158/1538-7445.Am10-5098 |
0.376 |
|
| 2010 |
Nasto RE, Serebriiskii I, Jablonski SA, Johnson MD, Clarke R, Weiner LM, Golemis EA. Abstract 2014: An estrogen receptor - centered network for probing anti-estrogen drug resistance with siRNA screening technology Cancer Research. 70: 2014-2014. DOI: 10.1158/1538-7445.Am10-2014 |
0.361 |
|
| 2010 |
Weiner LM, Tang Y, Wang S, Surana R, Xu W, Zhou Y, Marks JD, Golemis E. Abstract PL6-2: Antibody-initiated cancer immunotherapy Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-Pl6-2 |
0.786 |
|
| 2010 |
Deeken JF, Weiner LM. Supportive Care for Oncology Treatment: Not Just Icing on the Cake Annals of Internal Medicine. 153: 411. DOI: 10.1059/0003-4819-153-6-201009210-00010 |
0.391 |
|
| 2009 |
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.Ccr-09-0737 |
0.42 |
|
| 2009 |
Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet (London, England). 373: 1033-40. PMID 19304016 DOI: 10.1016/S0140-6736(09)60251-8 |
0.437 |
|
| 2009 |
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion On Therapeutic Targets. 13: 339-62. PMID 19236156 DOI: 10.1517/14712590902735795 |
0.426 |
|
| 2009 |
Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1443-51. PMID 19228745 DOI: 10.1158/1078-0432.Ccr-08-1231 |
0.332 |
|
| 2008 |
Urtishak S, Alpaugh RK, Weiner LM, Swaby RF. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. Biomarkers in Medicine. 2: 137-45. PMID 20477435 DOI: 10.2217/17520363.2.2.137 |
0.431 |
|
| 2008 |
Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG. Translational Research Working Group developmental pathway for immune response modifiers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5692-9. PMID 18794077 DOI: 10.1158/1078-0432.Ccr-08-1266 |
0.302 |
|
| 2008 |
Weiner LM. Cancer immunotherapy--the endgame begins. The New England Journal of Medicine. 358: 2664-5. PMID 18565858 DOI: 10.1056/Nejmp0803663 |
0.421 |
|
| 2008 |
Weiner LM. From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics. Cancer Journal (Sudbury, Mass.). 14: 147-8. PMID 18536553 DOI: 10.1097/PPO.0b013e3181772280 |
0.324 |
|
| 2008 |
Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. Journal of Immunology (Baltimore, Md. : 1950). 180: 6392-401. PMID 18424763 DOI: 10.4049/Jimmunol.180.9.6392 |
0.355 |
|
| 2008 |
Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. American Journal of Clinical Oncology. 31: 1-5. PMID 18376220 DOI: 10.1097/Coc.0B013E31805C142F |
0.359 |
|
| 2008 |
Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 502-8. PMID 18223225 DOI: 10.1158/1078-0432.Ccr-07-1509 |
0.391 |
|
| 2008 |
Weiner LM. Book Review Cancer Immunotherapy: Immune Suppression and Tumor Growth Edited by George C. Prendergast and Elizabeth M. Jaffee. 409 pp., illustrated. San Diego, CA, Elsevier Academic Press, 2007. $99.95. 978-0-12-372551-6 New England Journal of Medicine. 358: 1764-1765. DOI: 10.1056/Nejmbkrev59011 |
0.358 |
|
| 2007 |
Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy. 6: 1691-9. PMID 18032930 DOI: 10.4161/Cbt.6.11.4874 |
0.407 |
|
| 2007 |
Heimann DM, Weiner LM. Monoclonal antibodies in therapy of solid tumors. Surgical Oncology Clinics of North America. 16: 775-92, viii. PMID 18022544 DOI: 10.1016/J.Soc.2007.07.001 |
0.466 |
|
| 2007 |
Weiner LM. Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews. Cancer. 7: 701-6. PMID 17721434 DOI: 10.1038/Nrc2209 |
0.456 |
|
| 2007 |
Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. Journal of Immunology (Baltimore, Md. : 1950). 179: 2815-23. PMID 17709495 DOI: 10.4049/Jimmunol.179.5.2815 |
0.439 |
|
| 2007 |
Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 577-90. PMID 17667521 DOI: 10.1097/Cji.0B013E318064E7B2 |
0.399 |
|
| 2007 |
Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 455-67. PMID 17457220 DOI: 10.1097/Cji.0B013E31803Bb421 |
0.459 |
|
| 2007 |
Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 109: 170-9. PMID 17154393 DOI: 10.1002/Cncr.22402 |
0.425 |
|
| 2007 |
Carson WE, Allen A, Weiner LM, Cheever MA, Fox BA, Keilholz U, Wigginton JM, Sondel PM, Atkins MB, Hwu P. Immunotherapy comes of age: Overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer: Los Angeles, CA, USA, 27-29 October 2006 Expert Opinion On Biological Therapy. 7: 419-422. DOI: 10.1517/14712598.7.3.419 |
0.367 |
|
| 2007 |
Weiner LM. Emerging concepts in monocloal antibody therapy European Journal of Cancer, Supplement. 5: 442-443. DOI: 10.1016/S1359-6349(07)70092-7 |
0.359 |
|
| 2006 |
Cheng JD, Cohen SJ, Stzempkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Alpaugh RK, Lee H, Weiner LM, Meropol NJ. Phase II pharmacodynamic study of the fibroblast activation protein inhibitor Val-boro-Pro in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3594. PMID 27953472 DOI: 10.1200/jco.2006.24.18_suppl.3594 |
0.31 |
|
| 2006 |
Weiner LM, Borghaei H. Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Human Antibodies. 15: 103-11. PMID 17065741 DOI: 10.3233/Hab-2006-15305 |
0.451 |
|
| 2006 |
Movsas B, Diratzouian H, Hanlon A, Cooper H, Freedman G, Konski A, Sigurdson E, Hoffman J, Meropol NJ, Weiner LM, Coia L, Lanciano R, Stein J, Kister D, Eisenberg B. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. American Journal of Clinical Oncology. 29: 435-41. PMID 17023775 DOI: 10.1097/01.Coc.0000227480.41414.F2 |
0.318 |
|
| 2006 |
Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, ... ... Weiner LM, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 6: 125-32. PMID 16945168 DOI: 10.3816/Ccc.2006.N.029 |
0.411 |
|
| 2006 |
Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, Nakada MT. A review of antibody therapeutics and antibody-related technologies for oncology. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 351-64. PMID 16799330 DOI: 10.1097/01.Cji.0000199196.97845.C3 |
0.351 |
|
| 2006 |
Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1599-605. PMID 16533787 DOI: 10.1158/1078-0432.Ccr-05-2217 |
0.343 |
|
| 2006 |
Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Annals of Surgical Oncology. 13: 214-20. PMID 16418887 DOI: 10.1245/Aso.2006.01.001 |
0.329 |
|
| 2006 |
Weiner LM. Fully human therapeutic monoclonal antibodies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 1-9. PMID 16365595 DOI: 10.1097/01.Cji.0000192105.24583.83 |
0.375 |
|
| 2006 |
Tang Y, Alpaugh K, Lou J, Litwin S, Shaller C, Adams G, Marks J, Weiner L. High affinity promotes more effective ADCC by anti-HER2/neu monoclonal antibodies Journal of Clinical Oncology. 24: 2538-2538. DOI: 10.1200/Jco.2006.24.18_Suppl.2538 |
0.463 |
|
| 2006 |
Binyamin L, Borghaei H, Weiner LM. Cancer therapy with engineered monoclonal antibodies Update On Cancer Therapeutics. 1: 147-157. DOI: 10.1016/J.Uct.2006.05.002 |
0.454 |
|
| 2005 |
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biotherapy & Radiopharmaceuticals. 20: 603-13. PMID 16398612 DOI: 10.1089/Cbr.2005.20.603 |
0.343 |
|
| 2005 |
Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clinical Colorectal Cancer. 5: S71-80. PMID 16336752 DOI: 10.3816/Ccc.2005.S.010 |
0.429 |
|
| 2005 |
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 23: 1147-57. PMID 16151408 DOI: 10.1038/Nbt1137 |
0.502 |
|
| 2005 |
Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM. Global gene expression profiling of circulating tumor cells. Cancer Research. 65: 4993-7. PMID 15958538 DOI: 10.1158/0008-5472.Can-04-4330 |
0.407 |
|
| 2005 |
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 4: 351-60. PMID 15767544 DOI: 10.1158/1535-7163.Mct-04-0269 |
0.303 |
|
| 2005 |
Weiner LM, Belldegrun A, Rowinsky E, Crawford J, Lockbaum P, Huang S, Arends R, Schwab G, Figlin R. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies Journal of Clinical Oncology. 23: 3059-3059. DOI: 10.1200/Jco.2005.23.16_Suppl.3059 |
0.386 |
|
| 2005 |
Binyamin L, Alpaugh RK, Campbell KS, Borghaei H, Weiner LM. Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells. Blood. 106: 2456-2456. DOI: 10.1182/Blood.V106.11.2456.2456 |
0.389 |
|
| 2005 |
Weiner L. New Directions for Monoclonal Antibody Therapy Journal of Immunotherapy. 28: 644. DOI: 10.1097/01.Cji.0000191051.83813.76 |
0.37 |
|
| 2004 |
Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. The Journal of Biological Chemistry. 279: 53907-14. PMID 15471859 DOI: 10.1074/Jbc.M407888200 |
0.429 |
|
| 2004 |
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Research. 64: 6200-6. PMID 15342405 DOI: 10.1158/0008-5472.Can-03-2382 |
0.423 |
|
| 2004 |
Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. International Journal of Radiation Oncology, Biology, Physics. 58: 984-90. PMID 14967460 DOI: 10.1016/J.Ijrobp.2003.09.098 |
0.426 |
|
| 2004 |
Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 602-9. PMID 14966084 DOI: 10.1200/Jco.2004.12.034 |
0.347 |
|
| 2004 |
Tolcher AW, Mita M, Patnaik A, Rowinsky EK, Corey A, Fleming M, Fox NL, Weiner LM, Meropol NJ, Cohen R. A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors Journal of Clinical Oncology. 22: 3060-3060. DOI: 10.1200/Jco.2004.22.90140.3060 |
0.391 |
|
| 2004 |
Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy Drug Development Research. 61: 172-187. DOI: 10.1002/Ddr.10345 |
0.469 |
|
| 2003 |
Weiner LM, Carter P. The rollercoaster ride to anti-cancer antibodies. Nature Biotechnology. 21: 510-1. PMID 12721576 DOI: 10.1038/Nbt0503-510 |
0.442 |
|
| 2003 |
Benz C, Clark G, Conzen S, Dorn R, Fuqua S, Gralow J, Greene G, Heimann R, Hellman S, Lippman M, Rosen N, Weiner L. Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Research and Treatment. 78: 127-31. PMID 12611465 DOI: 10.1023/A:1022108507821 |
0.323 |
|
| 2003 |
von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annual Review of Medicine. 54: 343-69. PMID 12525678 DOI: 10.1146/Annurev.Med.54.101601.152442 |
0.509 |
|
| 2001 |
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. Journal of Immunology (Baltimore, Md. : 1950). 166: 6112-7. PMID 11342630 DOI: 10.4049/Jimmunol.166.10.6112 |
0.419 |
|
| 2001 |
Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. Journal of Immunological Methods. 251: 123-35. PMID 11292488 DOI: 10.1016/S0022-1759(00)00290-8 |
0.383 |
|
| 2001 |
Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biotherapy & Radiopharmaceuticals. 16: 9-11. PMID 11279802 DOI: 10.1089/108497801750095925 |
0.322 |
|
| 2001 |
Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). American Journal of Clinical Oncology. 24: 43-6. PMID 11232948 DOI: 10.1097/00000421-200102000-00007 |
0.347 |
|
| 2001 |
Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. Journal of Immunological Methods. 248: 1-6. PMID 11223064 DOI: 10.1016/S0022-1759(00)00338-0 |
0.354 |
|
| 2001 |
Diratzouian H, Movsas B, Hanlon AL, Freedman G, Hoffman J, Sigurdson E, Meropol N, Weiner L, Coia L, Lanciano R, Cooper H, Black S, Kister D, Eisenberg B. Phase II trial of preoperative chemoradiation with a hyperfractionated rt boost in locally advanced rectal cancer International Journal of Radiation Oncology Biology Physics. 51: 10. DOI: 10.1016/S0360-3016(01)01841-7 |
0.313 |
|
| 2000 |
Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene. 19: 6144-51. PMID 11156528 DOI: 10.1038/Sj.Onc.1204000 |
0.499 |
|
| 2000 |
Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Seminars in Oncology Nursing. 16: 2-12. PMID 11151455 DOI: 10.1053/Sonu.2000.19775 |
0.474 |
|
| 2000 |
Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules Nuclear Medicine and Biology. 27: 339-346. PMID 10938467 DOI: 10.1016/S0969-8051(00)00103-7 |
0.364 |
|
| 2000 |
Weiner LM. Bispecific antibodies in cancer therapy Cancer Journal. 6: S265-S271. PMID 10874497 DOI: 10.1016/S0952-7915(99)00015-1 |
0.327 |
|
| 1999 |
Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Current Opinion in Immunology. 11: 558-62. PMID 10508714 DOI: 10.1016/S0952-7915(99)00015-1 |
0.471 |
|
| 1999 |
McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis Molecular Immunology. 36: 433-445. PMID 10449096 DOI: 10.1016/S0161-5890(99)00057-7 |
0.426 |
|
| 1998 |
Alpaugh RK, Von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon Medical Oncology. 15: 191-198. PMID 9819796 DOI: 10.1007/Bf02821938 |
0.342 |
|
| 1998 |
McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM. Characterization of anti-mouse FcγRII single-chain Fv fragments derived from human phage display libraries Immunotechnology. 4: 71-87. PMID 9661816 DOI: 10.1016/S1380-2933(98)00006-2 |
0.33 |
|
| 1997 |
Weiner LM, Alpaugh RK, Von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins Cancer Immunology Immunotherapy. 45: 190-192. PMID 9435871 DOI: 10.1007/S002620050430 |
0.416 |
|
| 1997 |
Weiner LM. Biological therapies for gastrointestinal cancers Current Opinion in Oncology. 9: 373-379. PMID 9251888 DOI: 10.1097/00001622-199709040-00011 |
0.36 |
|
| 1997 |
Clark JI, Alpaugh RK, Von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment Cancer Immunology Immunotherapy. 44: 265-272. PMID 9247561 DOI: 10.1007/S002620050382 |
0.423 |
|
| 1997 |
Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1994-2007. PMID 9164211 DOI: 10.1200/Jco.1997.15.5.1994 |
0.428 |
|
| 1996 |
Von Mehren M, Weiner LM. Monoclonal antibody-based therapy Current Opinion in Oncology. 8: 493-498. PMID 8971469 DOI: 10.1097/00001622-199611000-00009 |
0.461 |
|
| 1996 |
Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site Journal of Molecular Biology. 263: 551-567. PMID 8918938 DOI: 10.1006/Jmbi.1996.0598 |
0.332 |
|
| 1996 |
Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Cancer Immunology, Immunotherapy : Cii. 42: 141-50. PMID 8640842 DOI: 10.1007/S002620050264 |
0.339 |
|
| 1996 |
Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection Journal of Molecular Biology. 255: 28-43. PMID 8568873 DOI: 10.1006/Jmbi.1996.0004 |
0.383 |
|
| 1996 |
Weiner LM, Marks J, Huston J, Schierb R, McCartney J, Wolf EJ, Mehren Mv, Adams GP. Determinants of selective tumor targeting by single-chain Fv molecules Immunotechnology. 2: 73. DOI: 10.1016/1380-2933(96)80684-1 |
0.317 |
|
| 1995 |
Schier R, Marks JD, Wolf EJ, Apelld G, Won C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library Immunotechnology. 1: 73-81. PMID 9373335 DOI: 10.1016/1380-2933(95)00007-0 |
0.415 |
|
| 1995 |
Haas NB, Schilder RJ, Nash S, Weiner LM, Catalano RC, Ozols RF, O'Dwyer PJ. A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer Investigational New Drugs. 13: 229-233. PMID 8729951 DOI: 10.1007/Bf00873805 |
0.34 |
|
| 1995 |
Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting C-erbB-2 and FcγRIII Journal of Hematotherapy. 4: 453-456. PMID 8581384 DOI: 10.1089/Scd.1.1995.4.453 |
0.461 |
|
| 1995 |
Langer CJ, Catalano R, Weiner LM, Scher R, Bagchi P, Saren B, Comis RL. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (m-VAC) in advanced, measurable breast carcinoma Cancer Investigation. 13: 150-159. PMID 7874568 DOI: 10.3109/07357909509011684 |
0.307 |
|
| 1995 |
Krigel RL, Padavic-Shaller K, Toomey C, Comis RL, Weiner LM. Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2 Journal of Immunotherapy With Emphasis On Tumor Immunology. 17: 161-170. PMID 7613642 DOI: 10.1097/00002371-199504000-00005 |
0.325 |
|
| 1995 |
Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Tai MS, Huston JS, Stafford WF, Bookman MA, Houston LL, Weiner LM. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration Cancer Immunology Immunotherapy. 40: 299-306. PMID 7600561 DOI: 10.1007/Bf01519629 |
0.31 |
|
| 1995 |
Adams GP, Weiner LM. Intracellular Single-Chain Fv Antibodies-A Knockout Punch for Neoplastic Cells? Gynecologic Oncology. 59: 6-7. PMID 7557617 DOI: 10.1006/Gyno.1995.1259 |
0.354 |
|
| 1995 |
Clark JI, Weiner LM. Biologic treatment of human cancer Current Problems in Cancer. 19: 185-262. PMID 7489640 DOI: 10.1016/S0147-0272(06)80005-X |
0.411 |
|
| 1994 |
Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer Investigational New Drugs. 12: 319-321. PMID 7775133 DOI: 10.1007/Bf00873047 |
0.349 |
|
| 1993 |
Weiner LM, Hudes GR, Kitson J, Walczak J, Watts P, Litwin S, O'Dwyer PJ. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen. Cancer Immunology, Immunotherapy : Cii. 36: 185-90. PMID 8439979 DOI: 10.1007/Bf01741090 |
0.354 |
|
| 1993 |
Weiner LM, Harvey E, Padavic-Shaller K, Willson JK, Walsh C, LaCreta F, Khazaeli MB, Kirkwood JM, Haller DG. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 13: 110-6. PMID 8318495 DOI: 10.1097/00002371-199302000-00005 |
0.417 |
|
| 1993 |
Garcia De Palazzo I, Klein-Szanto A, Weiner LM. Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies The International Journal of Biological Markers. 8: 233-239. DOI: 10.1177/172460089300800406 |
0.384 |
|
| 1992 |
de Palazzo IG, Kitson J, Gercel-Taylor C, Adams S, Weiner LM. Bispecific monoclonal antibody regulation of Fc gamma RIII-directed tumor cytotoxicity by large granular lymphocytes. Cellular Immunology. 142: 338-47. PMID 1535829 DOI: 10.1016/0008-8749(92)90295-Z |
0.445 |
|
| 1992 |
Weiner LM, Ring D, Holmes M, Lee G, de Palazzo IG. TARGETING LARGE GRANULAR LYMPHOCYTES TO TUMOR WITH BISPECIFIC ANTIBODIES Journal of Immunotherapy. 11: 151. DOI: 10.1097/00002371-199202000-00074 |
0.423 |
|
| 1992 |
Weiner LM. Book Review Biologic Therapy of Cancer Edited by Vincent T. DeVita, Jr., Samuel Hellman, and Steven A. Rosenberg. 800 pp., illustrated. Philadelphia, J.B. Lippincott, 1991. $125. New England Journal of Medicine. 326: 1297-1297. DOI: 10.1056/Nejm199205073261922 |
0.313 |
|
| 1991 |
Krigel RL, Padavic-Shaller KA, Rudolph AA, Young JD, Weiner LM, Konrad M, Comis RL. Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor. Journal of the National Cancer Institute. 83: 129-31. PMID 1988687 DOI: 10.1093/Jnci/83.2.129 |
0.304 |
|
| 1990 |
O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1497-503. PMID 2391557 DOI: 10.1200/Jco.1990.8.9.1497 |
0.341 |
|
| 1989 |
Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. Journal of the National Cancer Institute. 81: 775-81. PMID 2785605 DOI: 10.1093/Jnci/81.10.775 |
0.405 |
|
| 1987 |
Weiner LM. Monoclonal Antibody Therapy Aaohn Journal. 35: 175-178. DOI: 10.1177/216507998703500407 |
0.372 |
|
| Show low-probability matches. |